Background: X-linked inhibitor of apoptosis protein (XIAP) deficiency is a rare immunodeficiency that is characterized by recurrent hemophagocytic lymphohistiocytosis (HLH) and splenomegaly and sometimes associated with refractory inflammatory bowel disease (IBD). Although hematopoietic stem cell transplantation (HSCT) is the only curative therapy, the outcomes of HSCT for XIAP deficiency remain unsatisfactory compared with those for SLAM-associated protein deficiency and familial HLH.
Aim: To investigate the outcomes and adverse events of HSCT for patients with XIAP deficiency, a national survey was conducted.
Methods: A spreadsheet questionnaire was sent to physicians who had provided HSCT treatment for patients with XIAP deficiency in Japan.
Results: Up to the end of September 2016, 10 patients with XIAP deficiency had undergone HSCT in Japan, 9 of whom (90%) had survived. All surviving patients had received a fludarabine-based reduced intensity conditioning (RIC) regimen. Although 5 patients developed post-HSCT HLH, 4 of them survived after etoposide administration. In addition, the IBD associated with XIAP deficiency improved remarkably after HSCT in all affected cases.
Conclusion: The RIC regimen and HLH control might be important factors for successful HSCT outcomes, with improved IBD, in patients with XIAP deficiency.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101905 | PMC |
| http://dx.doi.org/10.1007/s10875-016-0348-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Management of Internal Fistulizing Crohn's Disease in a Child: More Than Meets the Eye.
Gastroenterology
October 2024
Paediatric Gastroenterology, Great Ormand Street Hospital, London, UK; Juliet Keidan Institute of Pediatric Gastroenterology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel.
Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in pediatric Inflammatory Bowel Disease: clinical characteristics and outcomes.
Eur J Pediatr
December 2024
Institute for Maternal and Child Health (IRCCS) "Burlo Garofolo", Via Dell' Istria 65, 34137, Trieste, Italy.
Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) in children with inflammatory bowel disease (IBD) has been reported only anecdotally. This study aimed at describing the clinical features and outcomes of children diagnosed with both IBD and HLH/MAS. Data on IBD and HLH/MAS characteristics, biochemical, microbiological and genetic assessments, treatments, and outcomes were collected from the Italian Pediatric IBD Registry and presented using descriptive statistics.
View Article and Find Full Text PDFHuman Genetic and Immunological Determinants of SARS-CoV-2 Infection and Multisystem Inflammatory Syndrome in Children.
Clin Exp Immunol
July 2024
Laboratory of Clinical Immunology, Inflammation and Allergies (LICIA), Faculty of Medicine and Pharmacy, Hassan II University, Casablanca 20250, Morocco.
Article Synopsis
- SARS-CoV-2 causes pneumonia and severe respiratory issues, especially in patients with genetic defects in type I interferon, impacting individuals differently based on age and gender.
- About 3-5% of critical COVID-19 patients under 60 years have genetic defects in interferon production, while around 15-20% of those over 70 show autoantibodies against type I interferons.
- This review discusses the links between genetic and immunological factors contributing to severe COVID-19 and pediatric multisystem inflammatory syndrome (MIS-C), emphasizing the need for more research to develop targeted treatments and strategies for future viral infections.
X-linked Inhibitor of Apoptosis (XIAP) Deficiency Complicated by Hemophagocytic Lymphohistiocytosis on Immunotherapy Leading to Acute Respiratory Distress Syndrome and Multiorgan Failure Secondary to Opportunistic Infections.
Cureus
June 2024
Internal Medicine, Hackensack University Medical Center, Hackensack, USA.
Article Synopsis
- * A 39-year-old man with XIAP deficiency faced severe complications including ARDS from PJP pneumonia and organ failure from a Mycobacterium infection.
- * The case underscores the difficulties in treating XIAP deficiency and highlights the need for better awareness and research to enhance patient outcomes.
Interleukin-1-mediated hyperinflammation in XIAP deficiency is associated with defective autophagy.
Blood
September 2024
Cell Biology Program, SickKids Research Institute, Toronto, ON, Canada.
Deficiency of X-linked inhibitor of apoptosis protein (XIAP) is a rare genetic condition that can present with recurrent episodes of hemophagocytic lymphohistiocytosis (HLH), though the exact mechanisms leading to this hyperinflammatory disorder are unclear. Understanding its biology is critical to developing targeted therapies for this potentially fatal disease. Here, we report on a novel multiexonic intragenic duplication leading to XIAP deficiency with recurrent HLH that demonstrated complete response to interleukin (IL)-1β blockade.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!